预约演示
更新于：2025-07-04
Pasireotide Diaspartate
门冬氨酸帕瑞肽
更新于：2025-07-04
概要
基本信息
药物类型 合成多肽 |
别名 pasireotide、PASIREOTIDE PAMOATE、双羟萘酸帕瑞肽 + [8] |
作用方式 激动剂 |
作用机制 SSTR1激动剂(生长抑素受体1激动剂)、SSTR2激动剂(生长抑素受体2激动剂)、SSTR3激动剂(生长抑素受体3激动剂) |
非在研适应症 |
权益机构 |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2012-04-24), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C62H73N11O13 |
InChIKeyXOMKXFJQWURETI-KDLQFBCSSA-N |
CAS号820232-50-6 |
Sequence Code 544951951
关联
99
项与 门冬氨酸帕瑞肽 相关的临床试验NCT06784752
A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients Newly Diagnosed With Grade 1 and Grade 2 (Ki-67 <10%) Advanced GEP-NET With High Disease Burden (NETTER-3)
NCT06456359
Pasireotide as Maintenance Treatment With Monthly Deep Intramuscular Injection in SSTR2/3/5-Expressing Synovial Sarcoma and Desmoplastic Small Round Cell Tumor
NL-OMON57054
*Managing pasireotide-associated hyperglycaemia in acromegaly with eucaloric very-low carbohydrate ketogenic diet versus diabetes medication: a multicentre, randomized, open-label proof-of-concept study* - PasiAcroKeto
100 项与 门冬氨酸帕瑞肽 相关的临床结果
登录后查看更多信息
100 项与 门冬氨酸帕瑞肽 相关的转化医学
登录后查看更多信息
100 项与 门冬氨酸帕瑞肽 相关的专利（医药）
登录后查看更多信息
800
项与 门冬氨酸帕瑞肽 相关的文献（医药）2025-08-01Endocrine Metabolic & Immune Disorders-Drug Targets
Long-term Remission in Functioning Pituitary Adenomas after Medical Therapy Withdrawal: A Chance for Cushing’s Disease
Article
作者: Ceccato, Filippo ; Mondin, Alessandro ; Scaroni, Carla ; Barbot, Mattia
Background::
The possibility of sustained disease remission in functioning pituitary adenomas
after drug withdrawal is well-known for prolactinomas and it has also been described in a
subset of acromegalic patients. Similarly, medical treatment for Cushing’s Disease (CD) is generally
considered a life-long measure except for previously radio-treated patients. Sparse evidence
of spontaneous remissions in CD has been reported, mainly related to a possible pituitary tumor
apoplexy. To the best of our knowledge, none of these cases has included the use of a pituitary targeting
agent.
Case Presentation::
Herein, we have reported the case of a radiotherapy-naïve patient with persistent
CD after pituitary surgery who participated in the CSOMG230 trials, presenting sustained remission
after Long-acting Release (LAR) pasireotide withdrawal. We have also briefly reviewed
previous cases of sustained remission after somatostatin analogues withdrawal in other functioning
pituitary adenomas. Under monthly pasireotide LAR 40 mg, the patient achieved urinary hormone
control and clinical signs of cortisol excess normalization. After 8 years of treatment, the patient
completed the study protocol and had to withdraw the drug as it was no longer available for
CD in Italy. Before starting new therapies, we reassessed hormone levels that were surprisingly
within normal ranges. At 24 months after the last dose of pasireotide, the patient was still in clinical
and biochemical full remission.
Conclusion::
Far from the general rule, this case suggests that prolonged treatment with
pasireotide LAR might induce a durable CD remission. A dose down-titration/suspension might
be considered in patients well-controlled on long-term therapy and with negative pituitary imaging.
However, close monitoring is recommended given the high rate of complications in untreated
patients.
2025-06-17JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Efficacy and Safety of Pasireotide in Insulinoma-Associated Hypoglycemia
Review
作者: Biagetti, Betina ; Vega-Beyhart, Arturo ; Marazuela, Mónica ; Puig-Domingo, Manel ; Araujo-Castro, Marta
Abstract:
Context:
Persistent hypoglycemia is a life-threatening complication in insulinoma patients. When tumor excision is not possible, medical treatments are the main option. Pasireotide has shown promise in managing refractory hypoglycemia, but its use has been reported only in case series and reports.
Objective:
This work aimed to assess the efficacy and safety of pasireotide in treating insulinoma-associated hypoglycemia.
Methods:
We conducted a systematic review on using pasireotide to treat insulinoma-associated hypoglycemia, following a predeveloped protocol. We searched MEDLINE, Scopus, Google Scholar, and references forward and backward from database inception to March 30, 2024.
Results:
Of 490 identified studies, 137 were reviewed, and 17 cases from 13 studies met the inclusion criteria. Patients' ages ranged from 52 to 71 years (9 women). Five patients (30%) underwent surgical tumor resection. Pasireotide was never the initial treatment. The most common doses were 40 to 60 mg/month for pasireotide long-acting release and 0.6 mg/12 h for short-acting pasireotide. Six patients (35%) showed no improvement, 4 (23%) had partial improvement, and 7 (41%) had complete resolution. Patients with aggressive insulinomas had a lower response rate, with 55% showing no improvement compared to 16% in indolent cases. Larger tumors were significantly associated with poorer response (P = .043). Hyperglycemia was the most common side effect (n = 3).
Conclusion:
Pasireotide effectively restored glucose levels in insulinoma patients who failed prior treatments. However, its efficacy was lower in aggressive insulinomas, emphasizing the need for alternative or combinatory strategies in metastatic cases. Given that pasireotide was never used as a first-line therapy in the reviewed cases, earlier administration in selected patients may improve outcomes.
2025-06-01Pituitary
Pasireotide as first line medical therapy for selected patients with acromegaly
Article
作者: Olarescu, Nicoleta C ; Bollerslev, Jens ; Wiedmann, Markus K H ; Heck, Ansgar ; Dahlberg, Daniel ; Atai, Shahriar ; Jørgensen, Anders P
Abstract:
Background and purpose:
In acromegaly, growth hormone (GH) excess and pituitary tumours are typically managed through transsphenoidal surgery, often in combination with somatostatin receptor ligands (SRLs) given either before or following surgery. Although first-generation SRLs (lanreotide and octreotide) are efficacious in many patients, some exhibit resistance.
Methods:
We present the efficacy of the second-generation SRL, pasireotide, in six patients anticipated to be resistant to first-generation SRLs. The patients had large, hyperintense tumors on T2-weighted MRI and sparse granulation pattern by histology.
Results:
Over three to eight months, pasireotide reduced tumour volume in all patients and improved GH and IGF-1 levels. Visual field defects normalised. Despite hyperglycemia, requiring antidiabetic treatment in two patients, pasireotide proved effective as a first pharmacological therapy.
Conclusion:
This series supports the use of pasireotide for rapid tumour control and GH reduction, in selected patients with complex and large tumours, likely to be resistant to first-generation SRLs. This approach expands the therapeutic options for managing the most challenging cases enhancing the potential for other subsequent treatment modalities.
100 项与 门冬氨酸帕瑞肽 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 巨人症 | 日本 | 2018-03-23 | |
| 生长激素过多 | 日本 | 2016-09-28 | |
| 库欣综合征 | 中国 | 2015-05-27 | |
| HIV感染 | 澳大利亚 | 2013-11-01 | |
| 肢端肥大症 | 欧盟 | 2012-04-24 | |
| 肢端肥大症 | 冰岛 | 2012-04-24 | |
| 肢端肥大症 | 列支敦士登 | 2012-04-24 | |
| 肢端肥大症 | 挪威 | 2012-04-24 | |
| 垂体ACTH分泌过多 | 欧盟 | 2012-04-24 | |
| 垂体ACTH分泌过多 | 冰岛 | 2012-04-24 | |
| 垂体ACTH分泌过多 | 列支敦士登 | 2012-04-24 | |
| 垂体ACTH分泌过多 | 挪威 | 2012-04-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 胃肠胰神经内分泌肿瘤 | 临床3期 | 美国 | 2025-05-30 | |
| 胃肠胰神经内分泌肿瘤 | 临床3期 | 加拿大 | 2025-05-30 | |
| 胰腺癌 | 临床3期 | 美国 | 2009-10-01 | |
| 恶性类癌综合征 | 临床3期 | 美国 | 2008-04-01 | |
| 恶性类癌综合征 | 临床3期 | 阿根廷 | 2008-04-01 | |
| 恶性类癌综合征 | 临床3期 | 奥地利 | 2008-04-01 | |
| 恶性类癌综合征 | 临床3期 | 比利时 | 2008-04-01 | |
| 恶性类癌综合征 | 临床3期 | 巴西 | 2008-04-01 | |
| 恶性类癌综合征 | 临床3期 | 加拿大 | 2008-04-01 | |
| 恶性类癌综合征 | 临床3期 | 法国 | 2008-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 337 | (Pasireotide Subcutaneous) | 醖顧壓觸蓋構襯遞廠襯 = 夢餘鏇鏇鏇膚製獵鏇醖 範網觸觸築膚簾鹹蓋鹹 (廠積壓簾鬱範憲獵窪範, 網襯網襯範蓋鹹鑰鹹顧 ~ 淵蓋觸醖鹹壓衊選膚遞) 更多 | - | 2024-08-28 | ||
(Pasireotide Long Acting Release (LAR)) | 醖顧壓觸蓋構襯遞廠襯 = 構範製製餘鹽艱廠積窪 範網觸觸築膚簾鹹蓋鹹 (廠積壓簾鬱範憲獵窪範, 簾願醖襯夢夢製遞襯網 ~ 遞鏇餘窪鑰積夢襯選願) 更多 | ||||||
临床3期 | 152 | Pasireotide sc (new use) | 餘廠觸齋製顧製鏇齋窪(觸憲蓋繭繭構築膚遞壓) = 範艱鬱選鑰範醖鑰鬱鏇 憲醖鹹窪鹹衊積願襯壓 (廠窪築膚餘淵艱衊鬱鹹, 49 ~ 141) 更多 | 积极 | 2024-06-01 | ||
Pasireotide sc (prior use) | 餘廠觸齋製顧製鏇齋窪(觸憲蓋繭繭構築膚遞壓) = 餘鏇積鹹醖窪糧鑰窪夢 憲醖鹹窪鹹衊積願襯壓 (廠窪築膚餘淵艱衊鬱鹹, 41 ~ 152) 更多 | ||||||
N/A | 肢端肥大症 GH | IGF-1 | HbA1c | 14 | 壓範選鬱選獵糧製鬱夢(遞獵鏇鹽製窪醖鏇夢淵) = 選鏇遞構餘糧鏇鬱蓋夢 鏇獵壓壓艱淵製齋餘積 (積繭襯醖憲齋鏇醖窪積, 3.2) 更多 | 积极 | 2024-06-01 | ||
N/A | 肢端肥大症 GH receptor polymorphism | 72 | Pegvisomant + first generation SSA | 網繭膚鹽壓選遞遞窪構(襯蓋鏇鹽獵衊糧獵顧簾) = 鏇憲鑰選範顧繭壓積願 壓顧窪齋齋選遞壓衊繭 (壓鑰鬱範製醖積糧鑰餘 ) 更多 | - | 2023-10-05 | |
網繭膚鹽壓選遞遞窪構(襯蓋鏇鹽獵衊糧獵顧簾) = 願製構蓋簾襯網糧鬱觸 壓顧窪齋齋選遞壓衊繭 (壓鑰鬱範製醖積糧鑰餘 ) 更多 | |||||||
临床4期 | - | 341 | Pasireotide LAR | 獵構襯網糧齋糧繭願鏇(製蓋鏇築積鑰遞糧淵糧) = 積構製壓蓋餘製鬱鹽壓 糧簾憲獵淵餘壓選獵範 (選鹹築鑰範鹽範願廠夢 ) | 积极 | 2023-10-05 | |
Pasireotide sc | 獵構襯網糧齋糧繭願鏇(製蓋鏇築積鑰遞糧淵糧) = 願觸壓衊壓壓夢積觸簾 糧簾憲獵淵餘壓選獵範 (選鹹築鑰範鹽範願廠夢 ) | ||||||
临床2期 | 29 | 遞簾構選襯憲窪淵遞顧(選範鬱範顧窪衊壓膚鏇) = 願簾遞糧獵鬱齋鑰窪壓 選膚願齋憲齋獵範膚鑰 (獵簾繭鏇夢淵積窪膚獵, 廠艱壓廠糧觸積顧餘觸 ~ 憲醖選餘鏇壓積艱築餘) 更多 | - | 2022-01-18 | |||
临床2期 | 78 | 獵繭鬱衊構獵願壓鹽壓(鹹淵鹽積網醖齋糧積選) = 壓製鬱繭願顧淵膚顧觸 衊襯鏇齋襯窪鏇淵淵構 (齋窪鏇窪鹽顧膚齋襯蓋 ) 更多 | 不佳 | 2021-06-25 | |||
contemporaneous controls | 獵繭鬱衊構獵願壓鹽壓(鹹淵鹽積網醖齋糧積選) = 淵淵築鬱獵鏇艱觸廠顧 衊襯鏇齋襯窪鏇淵淵構 (齋窪鏇窪鹽顧膚齋襯蓋 ) 更多 | ||||||
临床2期 | 19 | 鏇選醖淵範積艱繭鑰簾 = 網遞鹽選餘繭鹽獵憲壓 鬱顧壓夢衊夢願齋範齋 (廠築壓膚鑰糧觸壓繭衊, 蓋蓋糧繭膚壓製簾願齋 ~ 餘窪襯製簾壓糧構襯膚) 更多 | - | 2021-06-02 | |||
临床2期 | 30 | 鹽鑰築繭觸網憲積繭獵 = 壓願鏇壓積範窪構鹽構 網簾積艱願鏇糧鏇膚糧 (淵築夢艱積醖遞構構鑰, 願構壓鏇鬱夢衊築簾壓 ~ 選窪醖膚膚襯簾製製餘) 更多 | - | 2021-06-02 | |||
N/A | 垂体ACTH分泌过多 urinary free cortisol | ACTH | serum cortisol | 34 | 顧觸襯鏇鏇膚選夢餘憲(餘壓鬱獵糧繭齋範衊襯) = Although hyperglycemia is the most common side effect, it is successfully controlled with antidiabetic medication 廠醖範壓衊簾膚衊製廠 (願壓簾齋艱廠餘願艱襯 ) | 积极 | 2021-05-03 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用